Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification

INTRODUCTION: Patients with end-stage kidney disease (ESKD) exhibit anemia, chronic kidney disease‒mineral bone disorder (CKD–MBD), and cardiovascular disease. The REN-001 and REN-002 phase II, multicenter, randomized studies examined safety, tolerability, and effects of sotatercept, an ActRIIA-IgG1...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Kidney Int Rep
Autores principales: Coyne, Daniel W., Singh, Hem N., Smith, William T., Giuseppi, Ana Carolina, Connarn, Jamie N., Sherman, Matthew L., Dellanna, Frank, Malluche, Hartmut H., Hruska, Keith A.
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier 2019
Materias:
Clinical Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6933454/
https://ncbi.nlm.nih.gov/pubmed/31891000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2019.08.001
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares